Inherited polygenic effects on common hematological traits influence clonal selection on JAK2 V617F and the development of myeloproliferative neoplasms
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2 V617F and the development of myeloproliferative neoplasms ; volume:56 ; number:2 ; day:17 ; month:1 ; year:2024 ; pages:273-280 ; date:2.2024
Nature genetics ; 56, Heft 2 (17.1.2024), 273-280, 2.2024
- Creator
-
Guo, Jing
Walter, Klaudia
Quiros, Pedro M.
Gu, Muxin
Baxter, E. Joanna
Danesh, John
Angelantonio, Emanuele Di
Roberts, David
Guglielmelli, Paola
Harrison, Claire N.
Godfrey, Anna L.
Green, Anthony R.
Vassiliou, George S.
Vuckovic, Dragana
Nangalia, Jyoti
Soranzo, Nicole
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41588-023-01638-x
- URN
-
urn:nbn:de:101:1-2404220921152.909549293112
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Guo, Jing
- Walter, Klaudia
- Quiros, Pedro M.
- Gu, Muxin
- Baxter, E. Joanna
- Danesh, John
- Angelantonio, Emanuele Di
- Roberts, David
- Guglielmelli, Paola
- Harrison, Claire N.
- Godfrey, Anna L.
- Green, Anthony R.
- Vassiliou, George S.
- Vuckovic, Dragana
- Nangalia, Jyoti
- Soranzo, Nicole
- SpringerLink (Online service)
Other Objects (12)
Myeloproliferative neoplasms: The era of JAK2 mutations and more…
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia
The implication of identifying JAK2 V617F in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
Association between JAK2 V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms
Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients
Myeloproliferative neoplasms: The era of JAK2 mutations and more…
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia
The implication of identifying JAK2 V617F in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
Association between JAK2 V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms
Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients
Myeloproliferative neoplasms: The era of JAK2 mutations and more…
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 V617F-induced myeloproliferative neoplasms
Oncogenic JAK2 activation causes PD-L1 expression, sensitizing myeloproliferative neoplasms to immune checkpoint inhibition
Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia
The implication of identifying JAK2 V617F in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
Association between JAK2 V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms